Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nSEATTLE, Aug. 3 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the\n"Company") today announced that clinical data relating to long-term treatment\nwith Stimuvax were presented at the International Association for the Study of\nLung Cancer's 13th World Conference on Lung Cancer in San Francisco on August\n1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer\nCentre, Ottawa, Ontario, involved 16 patients who received treatment with\nStimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients\nwith stage IIIb/IV non-small cell lung cancer (NSCLC).\n\n\nAs of the time of data analysis in April 2009, 10 of the 16 studied\npatients were alive without evidence of disease progression, of whom eight\ncontinued to receive therapy with Stimuvax after 6.3 to 8.2 years. The\nremaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8\nyears, respectively, and were without evidence of disease progression. Nine of\nthe 10 living patients had stage IIIb NSCLC upon entry to the trial, while one\nhad stage IV disease. Six of the 10 living patients had a complete response to\ntheir first-line chemotherapy or chemo-radiation, while four patients had\nstable disease. The remaining six of the 16 patients discontinued Stimuvax\nafter 2.0 to 5.1 years of treatment as a result of disease progression and are\ndeceased.\n\n\nProlonged treatment with Stimuvax was well-tolerated in this trial. The\nmost common treatment-related adverse events were injection-site reactions,\nwhich tended to diminish after the first year of treatment. There was no\nevidence of autoimmune reactions with prolonged use.\n\n\nThe Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was\nconducted by Oncothyreon, with patient enrollment concluding in 2003.\nLong-term follow-up of these patients was conducted by Merck KGaA of\nDarmstadt, Germany, which assumed the clinical development of Stimuvax in\n2007. Merck KGaA is responsible for the world-wide development and\ncommercialization of Stimuvax under license from Oncothyreon and is currently\nconducting Phase 3 trials of Stimuvax in both NSCLC and breast cancer.\n\n\nAbout Stimuvax\n\n\nStimuvax is an investigational therapeutic cancer vaccine designed to\ninduce an immune response to cancer cells that express MUC1, a glycoprotein\nant...

More updates from Cascade Copper Corp.